Switch theme
Sign up to access all valuation multiples
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
2018
50
LTM Revenue $9.5M
Last FY EBITDA -$65.5M
-$10.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pyxis Oncology has a last 12-month revenue (LTM) of $9.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pyxis Oncology achieved revenue of $16.1M and an EBITDA of -$65.5M.
Pyxis Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pyxis Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.5M | XXX | $16.1M | XXX | XXX | XXX |
| Gross Profit | $9.2M | XXX | $15.7M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$65.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -406% | XXX | XXX | XXX |
| EBIT | -$91.6M | XXX | -$68.5M | XXX | XXX | XXX |
| EBIT Margin | -967% | XXX | -424% | XXX | XXX | XXX |
| Net Profit | -$81.4M | XXX | -$77.3M | XXX | XXX | XXX |
| Net Margin | -860% | XXX | -479% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pyxis Oncology's stock price is $1.
Pyxis Oncology has current market cap of $75.0M, and EV of -$10.6M.
See Pyxis Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$10.6M | $75.0M | XXX | XXX | XXX | XXX | $-1.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pyxis Oncology has market cap of $75.0M and EV of -$10.6M.
Pyxis Oncology's trades at -0.7x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Pyxis Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pyxis Oncology has a P/E ratio of -0.9x.
See valuation multiples for Pyxis Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $75.0M | XXX | $75.0M | XXX | XXX | XXX |
| EV (current) | -$10.6M | XXX | -$10.6M | XXX | XXX | XXX |
| EV/Revenue | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | -1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPyxis Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.7M for the same period.
Pyxis Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pyxis Oncology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pyxis Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -406% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 364% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 521% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pyxis Oncology acquired XXX companies to date.
Last acquisition by Pyxis Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Pyxis Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pyxis Oncology founded? | Pyxis Oncology was founded in 2018. |
| Where is Pyxis Oncology headquartered? | Pyxis Oncology is headquartered in United States of America. |
| How many employees does Pyxis Oncology have? | As of today, Pyxis Oncology has 50 employees. |
| Who is the CEO of Pyxis Oncology? | Pyxis Oncology's CEO is Dr. Lara S. Sullivan, M.D.. |
| Is Pyxis Oncology publicy listed? | Yes, Pyxis Oncology is a public company listed on NAS. |
| What is the stock symbol of Pyxis Oncology? | Pyxis Oncology trades under PYXS ticker. |
| When did Pyxis Oncology go public? | Pyxis Oncology went public in 2021. |
| Who are competitors of Pyxis Oncology? | Similar companies to Pyxis Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pyxis Oncology? | Pyxis Oncology's current market cap is $75.0M |
| What is the current revenue of Pyxis Oncology? | Pyxis Oncology's last 12 months revenue is $9.5M. |
| What is the current EV/Revenue multiple of Pyxis Oncology? | Current revenue multiple of Pyxis Oncology is -1.1x. |
| Is Pyxis Oncology profitable? | Yes, Pyxis Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
